Sec Form 3 Filing - Access Industries Holdings LLC @ Anchiano Therapeutics Ltd. - 2020-01-01

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Access Industries Holdings LLC 2. Issuer Name and Ticker or Trading Symbol Anchiano Therapeutics Ltd. [ ANCN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 40 WEST 57TH ST, 28TH FL 3. Date of Earliest Transaction (MM/DD/YY) 01/01/2020 (Street) NEW YORK, NY10019 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares 6,521,753 ( 1 ) D ( 2 ) Ordinary Shares 6,911,166 ( 3 ) D ( 4 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrants $ 1.932 ( 5 ) ( 6 ) ( 5 )( 6 ) 06/29/2023 Ordinary Shares 2,396,496 ( 5 ) ( 6 ) D ( 4 ) Employee stock options $ 0.47 ( 7 ) 11/13/2029 Ordinary Shares 55,000 D ( 4 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Access Industries Holdings LLC 40 WEST 57TH ST, 28TH FL NEW YORK, NY10019 X Clal Biotechnology Industries Ltd. 3 AZRIELI CENTER TRIANGLE TOWER 45 FLOOR TEL AVIV, L367023 X ACCESS INDUSTRIES, LLC 40 WEST 57TH ST, 28TH FL NEW YORK, NY10019 Affiliate of 10% Owner ACCESS INDUSTRIES MANAGEMENT, LLC 40 WEST 57TH ST, 28TH FL NEW YORK, NY10019 Affiliate of 10% Owner Blavatnik Len 40 WEST 57TH ST, 28TH FL NEW YORK, NY10019 Affiliate of 10% Owner Signatures /s/ Alejandro Moreno for Access Industries Holdings LLC 01/02/2020 Signature of Reporting Person Date /s/ Ofer Gonen (CEO) and Assaf Segal (CFO) for Clal Biotechnology Industries Ltd. 01/02/2020 Signature of Reporting Person Date /s/ Alejandro Moreno for Access Industries, LLC 01/02/2020 Signature of Reporting Person Date /s/ Alejandro Moreno for Access Industries Management, LLC 01/02/2020 Signature of Reporting Person Date /s/ Alejandro Moreno, as Attorney-in-Fact for Mr. Blavatnik 01/02/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Consists of 1,304,347 American Depositary Shares ("ADSs"), each of which represents five ordinary shares, no par value ("Ordinary Shares"), of the Issuer, evidenced by American Depositary Receipts. ( 2 )The securities reported are held directly by Access Industries Holdings LLC ("AIH") and may be deemed to be beneficially owned by Access Industries, LLC ("Access LLC"), Access Industries Management, LLC ("Management LLC") and Len Blavatnik, because Access LLC holds a majority of the outstanding voting interests in AIH, Management LLC controls Access LLC and AIH, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than AIH) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than AIH) is the beneficial owner of such securities for any purpose. ( 3 )Consists of 6,585,081 Ordinary Shares and 65,217 ADSs. ( 4 )The securities reported are held directly by Clal Biotechnology Industries Ltd. ("CBI"). AIH, Access LLC, Management LLC and Len Blavatnik may be deemed to beneficially own the securities held directly by CBI because Clal Industries Ltd. ("CI") is the controlling shareholder of CBI, AIH controls CI, Access LLC holds a majority of the outstanding interests in AIH, Management LLC controls Access LLC, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than CBI) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than CBI) is the beneficial owner of such securities for any purpose. ( 5 )On June 29, 2018, pursuant to a securities purchase agreement, dated March 29, 2018, between the Issuer and certain investors, CBI was issued a warrant to purchase 1,041,185 Ordinary Shares, as partial consideration for repayment of financing that was provided to the Issuer by CBI. Pursuant to the warrant agreement, dated June 20, 2018 (the "Warrant Agreement"), each warrant is exercisable for one Ordinary Share. ( 6 )CBI may elect to exercise the warrant in whole or in part and from time to time at any time until June 29, 2023, in cash or on a net issuance basis, in an amount equal to the aggregate exercise price for the Ordinary Shares being acquired upon exercise. The number of Ordinary Shares purchasable upon exercise of the warrant and the exercise price is subject to adjustments, as set forth in the Warrant Agreement. On February 14, 2019, in connection with the closing of the Issuer's initial public offering of ADSs, as a result of triggering certain price protection rights, the warrant was adjusted to provide for the purchase of an additional 1,355,311 Ordinary Shares from the Issuer. ( 7 )One-third of the options vest on November 10, 2020 and one-twelfth at the end of each calendar quarter thereafter, until fully vested.

Remarks: Exhibit List:Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.